Publication for CellMinerCDB
Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA; cBio Center, Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA, USA; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Charlestown, MA, USA; First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Centro De Estudos Em Células Tronco, Terapia Celular E Genética Toxicológica, Programa De PósGraduação Em Farmácia, Universidade Federal De Mato Grosso Do Sul, Campo Grande, Brazil
CellMinerCDB funding source(s)
Supported by the Center for Cancer Research, Intramural Program of the National Cancer Institute (Z01 BC006150), Ruth L. Kirschstein National Research Service Award (F32 CA192901), and the National Resource for Network Biology (NRNB) from the National Institute of General Medical Sciences (NIGMS) (P41 GM103504); by the WellcomeTrust (086375 and 102696); and by fellowships from the Japanese Society of Clinical Pharmacology and Therapeutics and the Japan Society for the Promotion of Science.
Be the first to review CellMinerCDB